The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of 10.7%, reaching US$16.36 ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Employees at banking giant JPMorgan Chase claimed in a new class action suit that the company mismanaged their benefits, ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The global Central Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR of 6.5%, ...

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences has its own resident expert in the fields of ...

As global markets grapple with ongoing trade uncertainties and recession fears, major indices like the S&P 500 and Dow Jones Industrial Average have seen consecutive weeks of negative returns. Amidst ...

Antibody-drug conjugates have emerged as ... “Advancements in ADCs could potentially spur biosimilar competition; however, the complex design of ADCs presents a greater challenge for rivals.